Based on the analysis of Bluebird Bio's profitability, liquidity, and operating efficiency, Bluebird bio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At present, Bluebird Bio's Net Debt is projected to increase significantly based on the last few years of reporting. The current year's Cash is expected to grow to about 283.9 M, whereas Total Current Liabilities is forecasted to decline to about 121.9 M. Key indicators impacting Bluebird Bio's financial strength include:
Investors should never underestimate Bluebird Bio's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Bluebird Bio's cash flow, debt, and profitability to make informed and accurate decisions about investing in Bluebird bio.
Net Income
(200.26 Million)
Bluebird
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Total Cashflows From Investing Activities
Sale Purchase Of Stock
Change To Inventory
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Account Receivables
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Investments
Change To Operating Activities
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Common Stock
Property Plant Equipment
Net Tangible Assets
Long Term Debt
Net Receivables
Good Will
Retained Earnings Total Equity
Capital Surpluse
Inventory
Deferred Long Term Liab
Non Current Liabilities Other
Intangible Assets
Long Term Investments
Short Long Term Debt Total
Long Term Debt Total
Short Long Term Debt
Capital Lease Obligations
Net Invested Capital
Net Working Capital
Capital Stock
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Net Income From Continuing Ops
Non Operating Income Net Other
Net Income Applicable To Common Shares
Tax Provision
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Bluebird Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bluebird Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Bluebird Bio's assets may result in an increase in income on the income statement.
Please note, the presentation of Bluebird Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bluebird Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bluebird Bio's management manipulating its earnings.
Bluebird Bio Stock Summary
Bluebird Bio competes with Mersana Therapeutics, Zentalis Pharmaceuticals, Y MAbs, Travere Therapeutics, and Madrigal Pharmaceuticals. bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts. Bluebird Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 518 people.
Foreign Associate
Canada
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Bluebird Bio's current stock value. Our valuation model uses many indicators to compare Bluebird Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bluebird Bio competition to find correlations between indicators driving Bluebird Bio's intrinsic value. More Info.
Bluebird bio is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Bluebird Bio's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Bluebird Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Bluebird bio Systematic Risk
Bluebird Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bluebird Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Bluebird bio correlated with the market. If Beta is less than 0 Bluebird Bio generally moves in the opposite direction as compared to the market. If Bluebird Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bluebird bio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bluebird Bio is generally in the same direction as the market. If Beta > 1 Bluebird Bio moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Bluebird Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bluebird Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Bluebird Bio growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.36
At present, Bluebird Bio's Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.
Bluebird Bio March 19, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Bluebird Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bluebird bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bluebird bio based on widely used predictive technical indicators. In general, we focus on analyzing Bluebird Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bluebird Bio's daily price indicators and compare them against related drivers.
When running Bluebird Bio's price analysis, check to measure Bluebird Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluebird Bio is operating at the current time. Most of Bluebird Bio's value examination focuses on studying past and present price action to predict the probability of Bluebird Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluebird Bio's price. Additionally, you may evaluate how the addition of Bluebird Bio to your portfolios can decrease your overall portfolio volatility.
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance